Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Augtyro (repotrectinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BMS, ZAI Lab

Drug class:

Multi-tyrosine kinase inhibitor, ALK inhibitor, ROS1 inhibitor, Trk inhibitor

Related drugs:

‹

BAY 2731954 (1)

dasatinib (215)

sorafenib (180)

anlotinib (139)

sunitinib (139)

lenvatinib (90)

gilteritinib (75)

cabozantinib tablet (74)

regorafenib (65)

midostaurin (51)

vandetanib (26)

cabozantinib capsule (24)

nintedanib (18)

unecritinib (6)

pexidartinib (6)

sorafenib nanoparticle (0)

crizotinib (312)

entrectinib (178)

alectinib (104)

lorlatinib (94)

brigatinib (50)

ensartinib (42)

iruplinalkib (11)

ALK inhibitor (0)

taletrectinib (5)

BAY 2731954 (1)

›

NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	repotrectinib Sensitive: A2 - Guideline repotrectinib Sensitive : A2	repotrectinib Sensitive: A2 - Guideline repotrectinib Sensitive : A2
ROS1 positive	Solid Tumor	ROS1 positive	Solid Tumor	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1
NTRK1 fusion	Non Small Cell Lung Cancer	NTRK1 fusion	Non Small Cell Lung Cancer	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1
NTRK3 fusion	Non Small Cell Lung Cancer	NTRK3 fusion	Non Small Cell Lung Cancer	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1
NTRK2 fusion	Non Small Cell Lung Cancer	NTRK2 fusion	Non Small Cell Lung Cancer	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	repotrectinib Sensitive: C2 – Inclusion Criteria repotrectinib Sensitive : C2	repotrectinib Sensitive: C2 – Inclusion Criteria repotrectinib Sensitive : C2
ROS1 G2032R	Non Small Cell Lung Cancer	ROS1 G2032R	Non Small Cell Lung Cancer	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3
ALK positive	Solid Tumor	ALK positive	Solid Tumor	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3